IDEXX Q2 2023 Earnings Highlights (NASDAQ: IDXX)



Revenue



Operating **Profit**



Diluted **Earnings Per Share**

\$944M \$296M \$2.67

Reported growth: +10% 31.4% of Revenue

Water

Organic growth: +10%

CAG

YoY change in basis points:

Reported growth: +71%

CAG Diagnostics Recurring

+1,060 bps Reported

Comparable growth:

+77%

Organic growth:

+12%



LPD

Revenue

\$867M

Comparable

0

\$43M

+1,130 bps

\$30M

Reported growth:

+11%

Reported growth:

Revenue

+10%

Reported growth:

Organic growth:

+11%

Organic growth:

+9%

Organic growth:


Revenue

0% +1%

Q2 Reported Organic **Net CAG Revenue** Revenue Growth Growth year over year year over year **CAG Diagnostics Recurring** \$762M +11% +12% IDEXX VetLab® Consumables \$304M +14% +15% \$97M +11% +12% Rapid Assay Products Reference Laboratory Dx and \$330M +9% +9% Consulting Services CAG Diagnostics Services and \$31M +13% +14% Accessories -6% -6% CAG Diagnostics Capital - Instruments \$34M Veterinary Software, Services and \$70M +12% +13% Diagnostic Imaging Systems

TOTAL	4,740	1,659	3,081
SediVue® Dx	616	308	308
New and competitive	1,335	439	896
Premium Hematology	1,863	594	1,269
Second	484	322	162
New and competitive	1,471	434	1,037
Catalyst	2,261	757	1,504
Q2 Premium Instrument Placements	WW	U.S.	Intl

IDEXX Premium Instruments Installed Base



For full financial data, non-GAAP reconciliations and cautionary language regarding forward-looking statements, please refer to IDEXX's 2023 second quarter earnings release issued on August 1, 2023 available at https://www.idexx.com/investors. Amounts presented may not recalculate due to rounding



IDEXX Q2 2023 Earnings Highlights (NASDAQ: IDXX)

2023 Growth and Financial Performance Outlook Commentary

- Updates 2023 estimates to reflect solid first half results, consistent expectations for solid second half growth and updated foreign exchange rate impact estimates
 - Increases revenue guidance to \$3,660 million \$3,715 million, reflecting 8.5% 10% growth as reported and organically, driven by projected CAG Diagnostics recurring revenue growth of 10% - 11% as reported and organically
 - Raises EPS outlook to \$9.64 \$9.90, a year-over-year increase of 20% 23% as reported and 24% 27% on a comparable basis, including ~12% combined growth benefit from a customer contract resolution payment in Q1 2023 and lapping of discrete 2022 R&D investments

Growth and Financial Performance Outlook		2023	
	Revenue	\$3,660	- \$3,715
W	Reported growth	8.5%	- 10%
	Organic growth	8.5%	- 10%
	CAG Diagnostics Recurring Revenue Growth		
	Reported growth	10%	- 11%
	Organic growth	10%	- 11%
	Operating Margin	29.3%	- 29.7%
	Reported margin expansion	270 bps	- 300 bps
	Negative impact of foreign exchange	~ 60 bps	
	Comparable margin expansion	330 bps	- 360 bps
	Positive impact of 2022 discrete R&D investments and customer contract resolution payment	~ 280 bps	
47	EPS	\$9.64	- \$9.90
	Reported growth	20%	- 23%
	Comparable growth	24%	- 27%
	Positive impact of 2022 discrete R&D investments and customer contract resolution payment	12 %	
	Other Key Metrics		
	Net interest expense	~ \$40 ~ \$9	
	Share-based compensation tax benefit		
	Effective tax rate	21.5% - 22%	
	Reduction in average shares outstanding	0.5 % - 1.0%	
	Operating Cash Flow	100% - 110% of net income	
	Free Cash Flow	80% - 90% of net income	
	Capital Expenditures	~ \$180	


Amounts in millions except per share data and percentages


For full financial data, non-GAAP reconciliations and cautionary language regarding forward-looking statements, please refer to IDEXX's 2023 second quarter earnings release issued on August 1, 2023 available at https://www.idexx.com/investors. Amounts presented may not recalculate due to rounding.




U.S. Companion Animal Practice Growth Update

As of June 30, 2023





Clinical Visit Growth Weighted Average Year-over-Year % Change Per Practice*



Total visits include clinical and non-clinical visits. In 2022, there were an estimated ~340 million U.S. total visits. Approximately 70% of estimated U.S. companion animal diagnostic sector revenue is from non-wellness visits.

Clinical visits are those where the reason for visit involves an interaction between a clinician and a pet.

Non-wellness visits include those for which the reason for visit is sickness, procedure or monitoring.

Wellness visits include those visits for which the reason for visit is an annual exam, vaccination, or routine check-up.

Source: IDEXX Practice Intelligence data; sample of ~8,800 practices representing six different practice information management systems, weighted to represent the country based on practice size and region.




Note that we estimate net new practice formation adds ~1% of incremental market growth per year beyond per practice growth.

Growth rate estimate with margin of error of +/ - 0.4% at a 95% confidence level.

U.S. Companion Animal Practice Growth Update As of June 30, 2023

Contributors to U.S. Companion Animal Diagnostic Revenue Growth per Practice**



^{**} Rounded to nearest 50 bps

Source: IDEXX Practice Intelligence data; sample of ~8,800 practices representing six different practice information management systems, weighted based on practice size and region to reflect market composition.



^{***} Diagnostic revenue per clinical visit includes volume/ intensity of Dx activity and net price realization.